Tacrine
The DOI matches its Crossref record; 33 of the 36 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tacrine (3)36–40 was withdrawn from the market primarily because of its hepatotoxicity.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [36]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Self-citationEVALUATION OF A MENTAL TEST SCORE FOR ASSESSMENT OF MENTAL IMPAIRMENT IN THE ELDERLY
HODKINSON, H. M. (1972) · Age and Ageing · doi:10.1093/ageing/1.4.233 · Cited by 1,692
Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer Type
Summers, W. K., Majovski, L. V., Marsh, G. M., Tachiki, K., & Kling, A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198611133152001 · Cited by 1,163
Knapp, M. J. (1994) · JAMA · doi:10.1001/jama.271.13.985 · Cited by 1,004
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease
Davis, K. L., Thal, L. J., Gamzu, E. R., Davis, C. S., Woolson, R. F., Gracon, S. I., Drachman, D. A., Schneider, L. S., Whitehouse, P. J., Hoover, T. M., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210293271801 · Cited by 626
Self-citation(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.3.390 · Cited by 408
Self-citationA Controlled Trial of Tacrine in Alzheimer's Disease
Farlow, M. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03490180055026 · Cited by 398
Tacrine in Alzheimer's disease
Eagger, S. A., Levy, R., & Sahakian, B. J. (1991) · The Lancet · doi:10.1016/0140-6736(91)92656-m · Cited by 361
Research works printed but not linked: 4
- Perry, 1978, Correlation of cholinergic abnormalities with senile plaques and mental scores in dementia, BMJ, ii, 147
- Schneider, 1991, Clinical pharmacology of aminoacridines in Alzheimer's disease, Neurology, 43, S64
- Freeman, 1991, Tacrine: a pharmacological review, Prog Neurobiol, 36, 257, 10.1016/0301-0082(91)90002-i · DOI · Paper page
- Schneider, 1991, Does blood pressure and age predict response to Alzheimer's disease? A preliminary report, Psychopharmacol Bull, 27, 301
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“For instance, the selective GSK3 β inhibitor OCM-51 ( 36 ) could achieve a bene fi cial balance between reducing tau phosphorylation and preventing overactivation of the β -catenin signaling pathway at appropriate doses.”
Kryger, G., Silman, I., & Sussman, J. L. (1999) · Structure · doi:10.1016/s0969-2126(99)80040-9 · Cited by 757
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Structure of acetylcholinesterase complexed with the nootropic alkaloid, (–)-huperzine A
Raves, M. L., Harel, M., Pang, Y.-P., Silman, I., Kozikowski, A. P., & Sussman, J. L. (1997) · Nature Structural & Molecular Biology · doi:10.1038/nsb0197-57 · Cited by 372
Highly Potent, Selective, and Low Cost Bis-tetrahydroaminacrine Inhibitors of Acetylcholinesterase
Pang, Y.-P., Quiram, P., Jelacic, T., Hong, F., & Brimijoin, S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.39.23646 · Cited by 344
Metadata
- Authors
- Davis, K. L., & Powchick, P.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- ORCID
- Davis, K.L.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1995-03
- Volume
- 345
- Issue
- 8950
- Pages
- 625-630
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4242215325
- Cited by
- 177
- References
- 36
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 3 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 5 · 2019: 6 · 2018: 3 · 2017: 5 · 2016: 8 · 2015: 4 · 2014: 5 · 2013: 9 · 2012: 5
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Keywords
- tacrine, antimalarial drugs, chloroquine resistance, malaria treatment
- MeSH terms
- Alzheimer Disease, Brain, Clinical Trials as Topic, Cognition Disorders, Double-Blind Method, Drug Interactions, Drug Tolerance, Humans, Palliative Care, Tacrine, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tacrine. https://app.cochat.ai/papers/10.1016/s0140-6736(95)90526-x
- The paper
- Davis, K. L., & Powchick, P. (1995). Tacrine. The Lancet. https://doi.org/10.1016/s0140-6736(95)90526-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.